Bright Minds Biosciences Inc. announced that the International Searching Authority reviewed its international patent application directed to phenethylamine compounds and issued a Written Opinion indicating that Bright Minds' core phenethylamine compounds of interest are novel and inventive over the searched prior art. Bright Minds recently filed an international patent application (assigned a filing number of PCT/CA2023/050003) directed at compounds that belong to the phenethylamine class of molecules, which the Company believes are potentially best in class compounds with an optimized short half-life, highly potent and extreme selectivity relative to other 5-HT(2A) agonists in development. Compounds from the Company's 5-HT(2A), and 5-HT(2 A) /5-HT(2C) programs are contained in this patent application, including its lead 5-HT (2A) agonist, BMB 202, as well as other backup and compounds of high interest from both programs. While the Written Opinion is non-binding, the Written Opinion is encouraging news and supports the view that Bright Minds has developed patentable phenethylamine compounds.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.57 CAD | 0.00% | +14.60% | -25.94% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.94% | 5.13M | |
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |
- Stock Market
- Equities
- DRUG Stock
- News Bright Minds Biosciences Inc.
- Bright Minds Biosciences Inc. Receives Favorable Written Opinion from the International Searching Authority for BMB-202